Vyome Holdings, Inc
About Vyome Holdings, Inc
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $319.7K
- Net income
- -$10.3M
- Total assets
- $6.5M
- Market cap
- $15.2M
- Gross margin
- 68.4%
- Operating margin
- -3269.4%
- Net margin
- -3277.2%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $319.7K
- Cost of revenue
- $100.9K
- Gross profit
- $218.8K
- Operating expenses
- $10.7M
- Operating income
- -$10.5M
- Net income
- -$10.5M
- EPS (basic)
- $-4.86
- EPS (diluted)
- $-4.86
Balance sheet
- Total assets
- $6.5M
- Current assets
- $5.4M
- Total liabilities
- $2.7M
- Current liabilities
- $2.7M
- Shareholders’ equity
- $3.8M
Cash flow
- Operating cash flow
- -$3.7M
- Investing cash flow
- -$4.9M
- Financing cash flow
- $8.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $15.2M
- EPS (diluted)
- $-4.86
- Shares outstanding
- 6.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 15, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $10.3M in FY2025.
- Gross margin of 68.4%, net margin -3277.2%.
- Trading 84% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vyome Holdings, Inc.
